HC Wainwright Confirms "Buy" Rating for Karyopharm Therapeutics

On Thursday, HC Wainwright reaffirmed a "buy" rating for Karyopharm Therapeutics (NASDAQ: KPTI) and set a price target of $7.00 per share in their latest research report. This endorsement highlights the confidence analysts have in the stock's potential growth.

Karyopharm Therapeutics has garnered attention from other analysts as well. For instance, Piper Sandler recently raised its target price for the company from $4.00 to $5.00 while assigning an "overweight" rating. This adjustment occurred on November 6th. Similarly, the Royal Bank of Canada issued an "outperform" rating with a target of $3.00 back on February 10th. Conversely, on November 22nd, StockNews.com downgraded Karyopharm's rating from "buy" to "hold." Overall, one analyst has classified the stock with a hold rating, while four others continue to endorse a buy rating. According to MarketBeat.com, Karyopharm has an average consensus rating of "Moderate Buy" and an average price target of $5.00.

Karyopharm Therapeutics Stock Performance

As of Thursday, shares of Karyopharm Therapeutics opened at $0.60. The company holds a market cap of approximately $75.71 million. With a price-to-earnings ratio of -0.53 and a beta of 0.06, the stock has displayed a 12-month low of $0.53 and a high of $1.70. Additionally, its 50-day simple moving average stands at $0.67, with a 200-day simple moving average at $0.76.

On February 19th, Karyopharm Therapeutics reported its quarterly earnings, revealing an EPS of ($0.24), which exceeded analysts' expectations of ($0.26) by $0.02. Looking ahead, analysts predict that Karyopharm will report earnings per share of -0.83 for the current year.

Institutional Holdings

In recent months, hedge funds have made notable changes to their positions in Karyopharm. Velan Capital Investment Management LP entered a new stake valued at around $27,000 during the fourth quarter. Likewise, Focus Partners Wealth and TD Waterhouse Canada Inc. acquired stakes worth approximately $31,000 and $32,000, respectively. Furthermore, Two Sigma Advisers LP increased its holdings by 145.5%, owning a total of 76,600 shares valued at about $52,000. Meanwhile, Opti Capital Management LP also took a new position worth roughly $85,000. Institutional investors and hedge funds now hold approximately 66.44% of Karyopharm's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company committed to the discovery, development, and commercialization of drug therapies that target nuclear export to treat cancer and other diseases. The company specializes in novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that particularly inhibit the nuclear export protein called exportin 1 (XPO1).

Karyopharm, rating, analysts